文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Dyslipidemia and aortic valve disease.

作者信息

Mata Pedro, Alonso Rodrigo, Pérez de Isla Leopoldo, Badimón Lina

机构信息

Fundación Hipercolesterolemia Familiar, Madrid, Spain.

Center for Advanced Metabolic Medicine and Nutrition, Santiago, Chile.

出版信息

Curr Opin Lipidol. 2021 Dec 1;32(6):349-354. doi: 10.1097/MOL.0000000000000794.


DOI:10.1097/MOL.0000000000000794
PMID:34629429
Abstract

PURPOSE OF REVIEW: Degenerative aortic stenosis (AS) is one of the most prevalent heart valve diseases in the adult population. The understanding of AS pathophysiology and involved risk factors have recently undergone a great advance, with low-density lipoprotein cholesterol (LDL-C), lipoprotein (a) [Lp(a)] and other clinical conditions taking on a relevant role. Although little is known about the prevention of AS, we can progressively find more evidence of the possible use of drugs to control risk factors as tools that may delay the progression to severe AS and aortic valve replacement. RECENT FINDINGS: Several factors have shown to be solid predictors of the development of AS. Mendelian randomization and observational studies on risk factors specifically lipid factors, such as hypercholesterolemia, Lp(a), proprotein convertase subtilisin/kexin type 9 and hypertension have provided meaningful new information. The SAFEHEART study has significantly contributed to define the role of LDL-C and Lp(a) in AS. SUMMARY: In this review we discuss the interrelationship of dyslipidemia, especially hypercholesterolemia and Lp(a) in the development and prognosis of valvular AS. New imaging tools may contribute to its early detection. Future studies with proprotein convertase subtilisin/kexin type 9 inhibitors and specific therapies to lower Lp(a) might contribute to delay AS development.

摘要

相似文献

[1]
Dyslipidemia and aortic valve disease.

Curr Opin Lipidol. 2021-12-1

[2]
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.

Circulation. 2013-7-24

[3]
PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.

J Clin Endocrinol Metab. 2016-9

[4]
Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA.

Int J Mol Sci. 2023-10-6

[5]
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.

JAMA Cardiol. 2020-6-1

[6]
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.

Atherosclerosis. 2018-10

[7]
From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.

Eur J Prev Cardiol. 2018-7-30

[8]
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.

J Clin Lipidol. 2017

[9]
'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering.

Curr Opin Lipidol. 2015-6

[10]
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

Endocr Pract. 2017-4

引用本文的文献

[1]
The Correlation Between Aortic Stenosis and the Incidence of Subsequent Ocular Surface Diseases.

In Vivo. 2025

[2]
The Correlation Between Aortic Stenosis and the Subsequent Incidence of Optic Neuropathy: A Population-based Cohort Study.

In Vivo. 2025

[3]
The Relationship Between Aortic Stenosis and the Possibility of Subsequent Macular Diseases: A Nationwide Database Study.

Diagnostics (Basel). 2025-3-18

[4]
The association between aortic stenosis and the risk of consecutive eyelid inflammatory diseases.

Int J Med Sci. 2025-2-18

[5]
Low-Density Lipoprotein Cholesterol, Type 2 Diabetes and Progression of Aortic Stenosis: The RED-CARPET Heart Valve Subgroup Cohort Study.

Rev Cardiovasc Med. 2024-8-7

[6]
Incidence of Acute Kidney Injury Post Transcatheter Aortic Valve Implantation (TAVI): A Single-Center Experience.

Cureus. 2024-7-23

[7]
Lipid Profile and Atrial Fibrillation: Is There Any Link?

Rev Cardiovasc Med. 2022-7-26

[8]
Aortic Valve Calcium Score: Applications in Clinical Practice and Scientific Research-A Narrative Review.

J Clin Med. 2024-7-11

[9]
Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review.

BMJ Open. 2023-3-29

[10]
Development and validation of a new prediction model for calcific aortic valve stenosis.

J Thorac Dis. 2022-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索